Source: Breathe, 14 (4) 338; 10.1183/20734735.026318
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Gabriella Long, Jasmine Wall. Precision medicine in COPD: review of mepolizumab for eosinophilic COPD. Breathe, 14 (4) 338; 10.1183/20734735.026318

Member's Comments

No comment yet.

Related content which might interest you: Medication use in COPD: systematic review and meta-analysis Source: Annual Congress 2007 - Treatment and care of COPD Year: 2007 Mepolizumab in COPD with eosinophilic bronchitis: A randomized clinical trial Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 Bronchodilators delivered by nebuliser versus pMDI for exacerbations of COPD - A Cochrane review Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Eosinophilic airway inflammation as a complication of COPD, and the usefulness of ICS on these cases Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Outcomes of COPD exacerbations - a report from the ERS COPD audit in Austria Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Hospital adherence to GOLD guidelines for COPD exacerbation. Results of the European CODP audit Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Misdiagnosed COPD: systematic review and meta-analysis Source: Annual Congress 2007 - Delivering respiratory care: the challenges for primary care Year: 2007 Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<% Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Compare clinical effectiveness of various types of bronchodilators in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial Source: Eur Respir J 2007; 29: 906-913 Year: 2007 The best papers in the ERJ: chronic airways diseases, including asthma and COPD Source: Virtual Congress 2020 – The European Respiratory Journal editor's view: our best papers of last year Year: 2020 Clinical experience with montelukast plus ICS vs. only ICS in non-asthmatic eosinophilic bronchitis (NAEB) in Indian patients Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001